Seres Therapeutics (NASDAQ:MCRB) Given “Neutral” Rating at Chardan Capital
Chardan Capital restated their neutral rating on shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) in a report released on Thursday morning, MarketBeat.com reports. They currently have a $6.00 target price on the biotechnology company’s stock, up from their prior target price of $1.25. MCRB has been the topic of several other research reports. The […]
Chardan Capital restated their neutral rating on shares of Seres Therapeutics (NASDAQ:MCRB – Free Report) in a report released on Thursday morning, MarketBeat.com reports. They currently have a $6.00 target price on the biotechnology company’s stock, up from their prior target price of $1.25. MCRB has been the topic of several other research reports. The […]
